Translational Research of Adult Stem Cell Therapy

Overview

Journal World J Cardiol

Publisher Baishideng Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2015 Dec 5

PMID 26635920

Citations 1

Authors

Gen Suzuki

Affiliations

Soon will be listed here.

Abstract

Congestive heart failure (CHF) secondary to chronic coronary artery disease is a major cause of morbidity and mortality world-wide. Its prevalence is increasing despite advances in medical and device therapies. Cell based therapies generating new cardiomyocytes and vessels have emerged as a promising treatment to reverse functional deterioration and prevent the progression to CHF. Functional efficacy of progenitor cells isolated from the bone marrow and the heart have been evaluated in preclinical large animal models. Furthermore, several clinical trials using autologous and allogeneic stem cells and progenitor cells have demonstrated their safety in humans yet their clinical relevance is inconclusive. This review will discuss the clinical therapeutic applications of three specific adult stem cells that have shown particularly promising regenerative effects in preclinical studies, bone marrow derived mesenchymal stem cell, heart derived cardiosphere-derived cell and cardiac stem cell. We will also discuss future therapeutic approaches.

Citing Articles

Heart-Derived Stem Cells in Miniature Swine with Coronary Microembolization: Novel Ischemic Cardiomyopathy Model to Assess the Efficacy of Cell-Based Therapy.

Suzuki G, Young R, Leiker M, Suzuki T Stem Cells Int. 2016; 2016:6940195.

PMID: 27738436 PMC: 5055979. DOI: 10.1155/2016/6940195.

References

Tang Y, Zhu W, Cheng M, Chen L, Zhang J, Sun T . Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res. 2009; 104(10):1209-16. PMC: 2756190. DOI: 10.1161/CIRCRESAHA.109.197723. View

Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M . Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2014; 116(4):653-64. DOI: 10.1161/CIRCRESAHA.116.304671. View

Leiker M, Suzuki G, Iyer V, Canty Jr J, Lee T . Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells. Cell Transplant. 2008; 17(8):911-22. PMC: 2856331. DOI: 10.3727/096368908786576444. View

Hatzistergos K, Quevedo H, Oskouei B, Hu Q, Feigenbaum G, Margitich I . Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010; 107(7):913-22. PMC: 3408082. DOI: 10.1161/CIRCRESAHA.110.222703. View

Tang J, Wang J, Guo L, Kong X, Yang J, Zheng F . Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Mol Cells. 2009; 29(1):9-19. DOI: 10.1007/s10059-010-0001-7. View

Mouquet F, Pfister O, Jain M, Oikonomopoulos A, Ngoy S, Summer R . Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circ Res. 2005; 97(11):1090-2. DOI: 10.1161/01.RES.0000194330.66545.f5. View

Meyer G, Wollert K, Lotz J, Steffens J, Lippolt P, Fichtner S . Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006; 113(10):1287-94. DOI: 10.1161/CIRCULATIONAHA.105.575118. View

Bruckner B, Razeghi P, Stetson S, Thompson L, Lafuente J, Entman M . Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. J Heart Lung Transplant. 2004; 23(1):36-42. DOI: 10.1016/s1053-2498(03)00103-7. View

Barile L, Messina E, Giacomello A, Marban E . Endogenous cardiac stem cells. Prog Cardiovasc Dis. 2007; 50(1):31-48. DOI: 10.1016/j.pcad.2007.03.005. View

10.

Pacifico A, Henry P . Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol. 2003; 14(7):764-75. DOI: 10.1046/j.1540-8167.2003.02543.x. View

11.

El-Sherif N, Turitto G . Risk stratification and management of sudden cardiac death: a new paradigm. J Cardiovasc Electrophysiol. 2003; 14(10):1113-9. DOI: 10.1046/j.1540-8167.2003.03204.x. View

12.

Shabbir A, Zisa D, Suzuki G, Lee T . Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol. 2009; 296(6):H1888-97. PMC: 2716100. DOI: 10.1152/ajpheart.00186.2009. View

13.

Aminzadeh M, Tseliou E, Sun B, Cheng K, Malliaras K, Makkar R . Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy. Eur Heart J. 2014; 36(12):751-62. PMC: 4368856. DOI: 10.1093/eurheartj/ehu196. View

14.

Shujia J, Haider H, Idris N, Lu G, Ashraf M . Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res. 2007; 77(3):525-33. DOI: 10.1093/cvr/cvm077. View

15.

Hofmann M, Wollert K, Meyer G, Menke A, Arseniev L, Hertenstein B . Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005; 111(17):2198-202. DOI: 10.1161/01.CIR.0000163546.27639.AA. View

16.

Williams A, Suncion V, McCall F, Guerra D, Mather J, Zambrano J . Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc. 2013; 2(3):e000140. PMC: 3698774. DOI: 10.1161/JAHA.113.000140. View

17.

Williams A, Hatzistergos K, Addicott B, McCall F, Carvalho D, Suncion V . Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation. 2012; 127(2):213-23. PMC: 3579523. DOI: 10.1161/CIRCULATIONAHA.112.131110. View

18.

Hall J, Grindle S, Han X, Fermin D, Park S, Chen Y . Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics. 2004; 17(3):283-91. DOI: 10.1152/physiolgenomics.00004.2004. View

19.

Gnecchi M, He H, Liang O, Melo L, Morello F, Mu H . Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11(4):367-8. DOI: 10.1038/nm0405-367. View

20.

Kajstura J, Rota M, Whang B, Cascapera S, Hosoda T, Bearzi C . Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res. 2004; 96(1):127-37. DOI: 10.1161/01.RES.0000151843.79801.60. View